Clinical Trial

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-01; most recent amendment 2024-05-05.
Status change: Not Yet Recruiting → Recruiting 2024-05-05
Trial Details
NCT Number NCT06251947
Lead Sponsor Shandong University
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Ovarian Cancer, Cervical Cancer
Enrollment 83 participants
Start Date 2024-04-15
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-05-07